NASDAQNEO

porcorex/iStock via Getty Images An injunction that blocked NeoGenomics (NASDAQ:NEO) from selling its cancer test, the RaDaR assay, was affirmed by an appeals court. A federal court in North Carolina has issued a preliminary injunction barring NeoGenomics (NEO) from manufacturing and selling its cancer test, the RaDaR assay, in aContinue Reading